Randomized clinical study· 1999

The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus

Nyholm B|Orskov L|Hove KY|Gravholt CH|Moller N|Alberti KG|Moyses C|Kolterman O|Schmitz O

Metabolism

DOI
10.1016/s0026-0495(99)90232-9
PubMed
10421239
Evidence level
moderate
Verification
verified

Summary

A clinical study evaluated pramlintide in adults with type 1 diabetes.

Limitations

Small short-term study|Requires insulin adjustment|Does not generalise to unlicensed analogues or obesity self-use

Linked peptides

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.